Bile Acid Receptor Farnesoid X Receptor: A Novel Therapeutic Target for Metabolic Diseases
Journal of Lipid and Atherosclerosis
; : 1-7, 2017.
Article
in En
| WPRIM
| ID: wpr-175108
Responsible library:
WPRO
ABSTRACT
Bile acid has been well known to serve as a hormone in regulating transcriptional activity of Farnesoid X receptor (FXR), an endogenous bile acid nuclear receptor. Moreover, bile acid regulates diverse biological processes, including cholesterol/bile acid metabolism, glucose/lipid metabolism and energy expenditure. Alteration of bile acid metabolism has been revealed in type II diabetic (T2D) patients. FXR-mediated bile acid signaling has been reported to play key roles in improving metabolic parameters in vertical sleeve gastrectomy surgery, implying that FXR is an essential modulator in the metabolic homeostasis. Using a genetic mouse model, intestinal specific FXR-null mice have been reported to be resistant to diet-induced obesity and insulin resistance. Moreover, intestinal specific FXR agonism using gut-specific FXR synthetic agonist has been shown to enhance thermogenesis in brown adipose tissue and browning in white adipose tissue to increase energy expenditure, leading to reduced body weight gain and improved insulin resistance. Altogether, FXR is a potent therapeutic target for the treatment of metabolic diseases.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Bile
/
Biological Phenomena
/
Body Weight
/
Adipose Tissue, Brown
/
Insulin Resistance
/
Bile Acids and Salts
/
Felodipine
/
Thermogenesis
/
Energy Metabolism
/
Adipose Tissue, White
Limits:
Animals
/
Humans
Language:
En
Journal:
Journal of Lipid and Atherosclerosis
Year:
2017
Type:
Article